You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港產草藥股Regencell Bioscience(RGC.US)市值與Lululemon相若 並超過超微電腦
總部設於香港、專注草藥的生科中概股Regencell Bioscience(RGC.US)本月初董事局宣布建議股份「一拆38」,周一(16日)生效,隔晚股價暴升283%,截至周一收市,Regencell總市值為297億美元,其市值目前與納斯達克上市的Lululemon(LULU.US)相若,並超越超微電腦(SMCI.US)。 Regencell旗下三種口服中藥配方聲稱可以治療注意力不足過動症和自閉症譜系障礙,並且只含有天然成分,不過市場對其療效和商業化程度知之甚少。 該股今年以來累升約460倍,年度虧損收窄至約440萬美元。一年前該股市值僅5,300萬美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account